Dose-Reduced Polio Vaccine via TRIS Buffer Inactivation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The high production costs and limited availability of Inactivated Poliovirus Vaccine (IPV) pose challenges for global supply, especially in low and middle-income countries, due to the need for more virus per dose, additional processing, and higher QC-testing requirements, making it 20-fold more expensive than Oral Polio Vaccine (OPV).
Innovation Solution
A method involving formaldehyde inactivation of Sabin IPV in TRIS buffer, combined with adsorption on aluminum hydroxide adjuvant, which reduces D-antigen losses and allows for at least 8-fold dose reduction, thereby decreasing production costs and increasing vaccine availability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional IPV formulation is used, then immunogenicity and safety are maintained, but production cost increases 20-fold compared to OPV
Solution Approach 1:
The patent applies parameter changes by modifying the buffer system during formaldehyde inactivation - specifically using TRIS buffer instead of phosphate buffer. This parameter change prevents aggregation of poliovirus particles and preserves D-antigen content, enabling dose reduction while maintaining immunogenicity. The result is a cost-effective IPV formulation that reduces production costs significantly while preserving vaccine efficacy.
Solution Approach 2:
The patent uses TRIS buffer as an intermediary substance during the formaldehyde inactivation process. This intermediary prevents harmful aggregation of virus particles and protects D-antigen integrity, allowing for reduced doses while maintaining immunogenicity. The TRIS buffer acts as a protective mediator between the formaldehyde inactivation step and the final vaccine formulation.
2Reliability
If more virus per dose is used in IPV, then immunogenicity is ensured, but production cost and processing requirements increase
Solution Approach 1:
The patent changes the buffer parameter from phosphate to TRIS during formaldehyde inactivation. This parameter change prevents virus particle aggregation and preserves D-antigen content, enabling reduced virus doses while maintaining immunogenicity. The TRIS buffer system allows for lower virus concentrations in the final formulation without compromising vaccine efficacy.
Solution Approach 2:
The patent converts the potentially harmful effect of formaldehyde inactivation (which can cause aggregation and antigen loss) into a beneficial process by using TRIS buffer. The TRIS buffer transforms the inactivation process into a controlled reaction that preserves virus integrity and D-antigen content, enabling dose reduction while maintaining immunogenicity.
3Reliability
If additional downstream processing is performed for IPV, then virus inactivation and purification are achieved, but production cost and processing time increase
Solution Approach 1:
The patent changes the buffer parameter during inactivation to TRIS buffer, which streamlines the downstream processing by preventing aggregation and preserving antigen integrity. This parameter change reduces the complexity and time required for purification and inactivation steps while maintaining vaccine reliability.
4Ease of manufacture
If phosphate buffer is used during formaldehyde inactivation, then inactivation process is simplified, but D-antigen losses occur due to aggregation
Solution Approach 1:
The patent changes the buffer parameter from phosphate to TRIS during formaldehyde inactivation. This parameter change prevents aggregation of poliovirus particles and preserves D-antigen content, eliminating the loss problem while maintaining process simplicity. The TRIS buffer system is just as easy to use as phosphate buffer but prevents the harmful aggregation effect.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in significantly reduced production costs and increased vaccine supply, making IPV more affordable and accessible, while maintaining immunogenicity and safety, by minimizing epitopic modifications and antigen loss during the inactivation process.
Implementation Method 1
formaldehyde inactivation of the poliovirus wherein the inactivation is carried out in presence of a buffer other than a phosphate buffer
Implementation Method 2
adsorption on aluminum hydroxide adjuvant
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention is directed to improved methods of Enterovirus inactivation by formaldehyde in presence of tromethamine buffer resulting in maximum recovery of D-antigen. Subsequent adsorption of said sIPV on aluminium hydroxide provides significantly dose reduced sIPV compositions.